EA201790867A1 - Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 - Google Patents
Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7Info
- Publication number
- EA201790867A1 EA201790867A1 EA201790867A EA201790867A EA201790867A1 EA 201790867 A1 EA201790867 A1 EA 201790867A1 EA 201790867 A EA201790867 A EA 201790867A EA 201790867 A EA201790867 A EA 201790867A EA 201790867 A1 EA201790867 A1 EA 201790867A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- smad7
- treatment
- methods
- smell
- oligonucleotide
- Prior art date
Links
- 101700026522 SMAD7 Proteins 0.000 title abstract 4
- 102000049873 Smad7 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065598P | 2014-10-17 | 2014-10-17 | |
| PCT/EP2015/074066 WO2016059239A1 (en) | 2014-10-17 | 2015-10-16 | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201790867A1 true EA201790867A1 (ru) | 2017-08-31 |
Family
ID=54330761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790867A EA201790867A1 (ru) | 2014-10-17 | 2015-10-16 | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10337004B2 (enExample) |
| EP (1) | EP3207136A1 (enExample) |
| JP (1) | JP2017532961A (enExample) |
| KR (1) | KR20170069262A (enExample) |
| CN (1) | CN107406851A (enExample) |
| AU (1) | AU2015332624A1 (enExample) |
| CA (1) | CA2964667A1 (enExample) |
| EA (1) | EA201790867A1 (enExample) |
| IL (1) | IL251717A0 (enExample) |
| MA (1) | MA43331A (enExample) |
| MX (1) | MX2017004973A (enExample) |
| WO (1) | WO2016059239A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| JP5719776B2 (ja) | 2008-11-13 | 2015-05-20 | ノグラ ファーマ リミテッド | アンチセンス組成物およびその作製および使用 |
| WO2013037970A1 (en) | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| US20170233736A1 (en) * | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| JP2019505598A (ja) * | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| WO2018122376A1 (en) * | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
| EP4139459A2 (en) * | 2020-04-24 | 2023-03-01 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1456380B1 (en) | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| JP5719776B2 (ja) | 2008-11-13 | 2015-05-20 | ノグラ ファーマ リミテッド | アンチセンス組成物およびその作製および使用 |
| CA2750584A1 (en) * | 2009-01-26 | 2010-07-29 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil |
| US9006198B2 (en) * | 2010-02-08 | 2015-04-14 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| WO2013037970A1 (en) * | 2011-09-15 | 2013-03-21 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
| NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| JP6502863B2 (ja) | 2013-03-15 | 2019-04-17 | ノグラ ファーマ リミテッド | 結腸直腸癌を処置する方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| JP2017532982A (ja) | 2014-10-17 | 2017-11-09 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体 |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| MA41271A (fr) | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| EP3356530A4 (en) | 2015-09-30 | 2019-04-10 | Celgene Alpine Investment Company II, LLC | TLR-MODULATORS AND METHOD OF USE |
| EP3355896A2 (en) | 2015-09-30 | 2018-08-08 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
-
2015
- 2015-10-16 US US15/519,468 patent/US10337004B2/en not_active Expired - Fee Related
- 2015-10-16 MX MX2017004973A patent/MX2017004973A/es unknown
- 2015-10-16 EA EA201790867A patent/EA201790867A1/ru unknown
- 2015-10-16 AU AU2015332624A patent/AU2015332624A1/en not_active Abandoned
- 2015-10-16 MA MA043331A patent/MA43331A/fr unknown
- 2015-10-16 WO PCT/EP2015/074066 patent/WO2016059239A1/en not_active Ceased
- 2015-10-16 KR KR1020177012839A patent/KR20170069262A/ko not_active Withdrawn
- 2015-10-16 EP EP15781642.2A patent/EP3207136A1/en not_active Withdrawn
- 2015-10-16 CA CA2964667A patent/CA2964667A1/en not_active Abandoned
- 2015-10-16 CN CN201580069041.9A patent/CN107406851A/zh active Pending
- 2015-10-16 JP JP2017520449A patent/JP2017532961A/ja active Pending
-
2017
- 2017-04-13 IL IL251717A patent/IL251717A0/en unknown
-
2019
- 2019-05-21 US US16/418,108 patent/US20190338283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016059239A1 (en) | 2016-04-21 |
| MX2017004973A (es) | 2017-12-07 |
| AU2015332624A1 (en) | 2017-05-04 |
| KR20170069262A (ko) | 2017-06-20 |
| JP2017532961A (ja) | 2017-11-09 |
| CA2964667A1 (en) | 2016-04-21 |
| EP3207136A1 (en) | 2017-08-23 |
| US20170240893A1 (en) | 2017-08-24 |
| US20190338283A1 (en) | 2019-11-07 |
| MA43331A (fr) | 2017-08-23 |
| CN107406851A (zh) | 2017-11-28 |
| IL251717A0 (en) | 2017-06-29 |
| US10337004B2 (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790867A1 (ru) | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 | |
| EA201692537A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| EA201690526A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| PH12017500669A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | |
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| EA201692370A1 (ru) | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
| WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
| EA201591707A1 (ru) | КОМПОЗИЦИИ иРНК КОМПОНЕНТА КОМПЛЕМЕНТА C5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HK1245800A1 (zh) | 被取代的核苷、核苷酸及其类似物 | |
| NZ730296A (en) | Modified double-stranded rna agents | |
| DK3265102T3 (da) | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling | |
| EA201790802A1 (ru) | Соединения против tnf | |
| PL3512863T3 (pl) | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA | |
| MX388737B (es) | Oligonucleótidos terapéuticos. | |
| EA201791471A1 (ru) | Способы применения антисмысловых олигонуклеотидов smad7 | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
| EP3307326A4 (en) | METHOD FOR TREATING LEPTOMENINGEAL CARCINOMATOSIS | |
| AR132165A2 (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) | |
| HK1241287A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | |
| PL410511A1 (pl) | Sposób amplifikacji DNA w reakcji łańcuchowej polimerazy w czasie rzeczywistym za pomocą starterów metylo-specyficznych dla promotora genu DCLKI |